AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28394819 — intervention group
Group type: COMPARATOR
Intervention: Noisy atmosphere during SCT assessment
Number of subjects: 42
Study 28394819 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet atmosphere for year 1 and 2 residents
Number of subjects: 42
Study 28394819 — intervention group
Group type: COMPARATOR
Intervention: Noisy atmosphere for year 1 and 2 residents
Number of subjects: 42
Study 28394819 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet atmosphere for year 3 and 4 residents
Number of subjects: 42
Study 28394819 — intervention group
Group type: COMPARATOR
Intervention: Noisy atmosphere for year 3 and 4 residents
Number of subjects: 42
Study 25998279 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline
Number of subjects: 130
Study 25998279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 23595943 — intervention group
Group type: EXPERIMENTAL
Intervention: NCC-AT
Number of subjects: 18
Study 21242842 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative fever
Number of subjects: 578
Study 21242842 — intervention group
Group type: EXPERIMENTAL
Intervention: LMD with postoperative fever
Number of subjects: 578
Study 21242842 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDF with postoperative fever
Number of subjects: 578
Study 21242842 — intervention group
Group type: EXPERIMENTAL
Intervention: LDF with postoperative fever
Number of subjects: 578
Study 19741381 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of structured checklist for ICU handoffs
Number of subjects: 332
Study 19741381 — intervention group
Group type: COMPARATOR
Intervention: No checklist used
Number of subjects: 332
Study 18035002 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy
Number of subjects: 100
Study 18035002 — intervention group
Group type: COMPARATOR
Intervention: Ferguson haemorrhoidectomy
Number of subjects: 100
Study 17249431 — intervention group
Group type: EXPERIMENTAL
Intervention: CollaCote
Number of subjects: 25
Study 17249431 — intervention group
Group type: COMPARATOR
Intervention: No barrier
Number of subjects: 25
Study 12728088 — intervention group
Group type: COMPARATOR
Intervention: Thyroxine (T4) alone (group 1)
Number of subjects: 14
Study 12728088 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) plus Triiodothyronine (T3) (group 2)
Number of subjects: 14
Study 12728088 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched infants)
Number of subjects: 14
Study 10335757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.8 mg daily
Number of subjects: 41
Study 10335757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8937947 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative quality improvement program
Number of subjects: 1402
Study 8937947 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programs on CHF, feedback of Phase I data, clinical care pathway design, improvement of emergency department management, patient education and discharge planning
Number of subjects: 1402
Study 2020613 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 5 mg
Number of subjects: 241
Study 2020613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 241
Study 2020613 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 25 mg
Number of subjects: 241
Study 2020613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 241
Study 2020613 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 25 mg and Ibuprofen 400 mg
Number of subjects: 241
Study 2020613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 6982803 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) tablets, 0.5 mg, four times daily for five days
Number of subjects: 20
Study 6982803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31693429 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin with bendamustine and rituximab (pola‐BR)
Number of subjects: 107
Study 31693429 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine and rituximab (BR)
Number of subjects: 107
Study 31693429 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin with bendamustine and obinutuzumab (pola‐BG)
Number of subjects: 107
Study 28727183 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led smartphone-based self-management programme
Number of subjects: 128
Study 28727183 — intervention group
Group type: COMPARATOR
Intervention: Existing nurse-led diabetes service
Number of subjects: 128
Study 26489809 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 10 mg daily (doubled after 12 weeks)
Number of subjects: 441
Study 26489809 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride plus Hydrochlorothiazide (5 mg + 12.5 mg daily, doubled after 12 weeks)
Number of subjects: 441
Study 26489809 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg daily (doubled after 12 weeks)
Number of subjects: 441
Study 26489809 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride plus Hydrochlorothiazide
Number of subjects: 441
Study 26489809 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 441
Study 26489809 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 441
Study 25016507 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.5% (0.5 mL/kg)
Number of subjects: 56
Study 25016507 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine 0.2% (0.5 mL/kg)
Number of subjects: 56
Study 22653094 — intervention group
Group type: EXPERIMENTAL
Intervention: Eperisone with tramadol (100 mg/day)
Number of subjects: 60
Study 22653094 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine with tramadol (100 mg/day)
Number of subjects: 60
Study 20367520 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 15
Study 20367520 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg etoricoxib
Number of subjects: 15
Study 20367520 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 18533562 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscope under midazolam-induced sleep
Number of subjects: 132
Study 18533562 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical examination and video laryngoscope when awake
Number of subjects: 132
Study 16053212 — intervention group
Group type: EXPERIMENTAL
Intervention: PETN-100
Number of subjects: 25
Study 16053212 — intervention group
Group type: COMPARATOR
Intervention: PETN-50
Number of subjects: 25
Study 11954883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lavage with 5 l of physiological fluid
Number of subjects: 98
Study 11954883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lavage with 10 l of physiological fluid
Number of subjects: 98
Study 11954883 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular lavage with 0.5-1.5 l of physiological fluid
Number of subjects: 98
Study 10512405 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin, 10 mg/kg per day in two divided doses for 18+/‐20 months
Number of subjects: 24
Study 8554930 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA infusion (0.1, 0.2, 0.5, 1.0 and 2.0 mg kg‐1 h‐1)
Number of subjects: 8
Study 8554930 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA infusion
Number of subjects: 8
Study 2028917 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE (ice and water cooling system)
Number of subjects: 9
Study 2028917 — intervention group
Group type: EXPERIMENTAL
Intervention: FREON (Freon-based cooling system)
Number of subjects: 9
Study 2028917 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS (Coast Guard chemical response suit)
Number of subjects: 9
Study 2028917 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (self‐contained breathing apparatus with shorts, shirt, helmet, and shoes)
Number of subjects: 9
Study 7005939 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening procedure
Number of subjects: 0
Study 7005939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study 31121302 — intervention group
Group type: EXPERIMENTAL
Intervention: Predefined center and surgeon credentials established to manage learning effects
Number of subjects: 50
Study 31121302 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified randomization by site
Number of subjects: 50
Study 31121302 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified randomization by surgeon
Number of subjects: 50
Study 31121302 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent adjustment in analysis for learning and clustering effects
Number of subjects: 50
Study 31121302 — intervention group
Group type: EXPERIMENTAL
Intervention: Funder led changes in response to referees
Number of subjects: 50
Study 28057077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice ingestion with a long rest interval (20 min)
Number of subjects: 7
Study 28057077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice ingestion with a short rest interval (5 min)
Number of subjects: 7
Study 28057077 — intervention group
Group type: COMPARATOR
Intervention: Cold water ingestion (4 °C)
Number of subjects: 7
Study 27180353 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step self-etch adhesive (1-SEA)
Number of subjects: 200
Study 27180353 — intervention group
Group type: COMPARATOR
Intervention: 3-step etch-and-rinse adhesive (3-E&RA)
Number of subjects: 200
Study 22960432 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompting form
Number of subjects: 60
Study 20542976 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month multidisciplinary intervention (n=33)
Number of subjects: 75
Study 20542976 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n=32)
Number of subjects: 75
Study 19470318 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-pseudomonal treatment (cycled therapy) including inhaled tobramycin (300 mg BID for 28 days) and oral ciprofloxacin (15-20 mg/kg BID for 14 days)
Number of subjects: 306
Study 19470318 — intervention group
Group type: COMPARATOR
Intervention: Culture-based therapy based on recovery of Pseudomonas aeruginosa from quarterly respiratory cultures
Number of subjects: 306
Study 17223346 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) of gastrocnemius and soleus at three different timings during normal gait
Number of subjects: 5
Study 17223346 — intervention group
Group type: COMPARATOR
Intervention: Unstimulated trials
Number of subjects: 5
Study 12937809 — intervention group
Group type: EXPERIMENTAL
Intervention: Butea superba
Number of subjects: 0
Study 11100891 — intervention group
Group type: EXPERIMENTAL
Intervention: Frisby test for stereopsis assessment
Number of subjects: 0
Study 8737105 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50-100 mg b.i.d. (n = 106)
Number of subjects: 210
Study 8737105 — intervention group
Group type: COMPARATOR
Intervention: Xamoterol 100-200 mg b.i.d. (n = 104)
Number of subjects: 210
Study 1534312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 540
Study 1534312 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 540
Study 1534312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard
Number of subjects: 540
Study 6397848 — intervention group
Group type: EXPERIMENTAL
Intervention: De-Nol tablets (four times daily)
Number of subjects: 50
Study 6397848 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine tablets (400 mg, twice daily)
Number of subjects: 50
Study 6397848 — intervention group
Group type: EXPERIMENTAL
Intervention: De-Nol tablets
Number of subjects: 50
Study 6397848 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine tablets
Number of subjects: 50
Study 30664828 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 keto fluprostenol isopropyl ester gel (80 µgr/mL)
Number of subjects: 40
Study 30664828 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 40
Study 25331010 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 120
Study 26034917 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with aspirin
Number of subjects: 0
Study 26034917 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 23704972 — intervention group
Group type: EXPERIMENTAL
Intervention: Painless examination (general clinical exam)
Number of subjects: 0
Study 23704972 — intervention group
Group type: COMPARATOR
Intervention: Painful examination (pocketing and bleeding on probing exam)
Number of subjects: 0
Study 21303639 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM) patients (older than 70 years)
Number of subjects: 100
Study 21303639 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM) patients (younger than 70 years)
Number of subjects: 100
Study 21303639 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM) patients
Number of subjects: 100
Study 21303639 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study 19577798 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg twice daily
Number of subjects: 404
Study 19577798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 17570951 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (14.0 +/- 5.0 mg/day)
Number of subjects: 23
Study 17570951 — intervention group
Group type: COMPARATOR
Intervention: Perazine (360.0 +/- 196.0 mg/day) + Carbamazepine (404.0 +/- 229.0 mg/day)
Number of subjects: 23
Study 15549464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray (5 times)
Number of subjects: 168
Study 15549464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray (10 times)
Number of subjects: 168
Study 15549464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline 1 ml)
Number of subjects: 168
Study 11298666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate (1600 mg)
Number of subjects: 251
Study 11298666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 9813517 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow ventilation (1 litre min‐1)
Number of subjects: 20
Study 9813517 — intervention group
Group type: COMPARATOR
Intervention: High-flow ventilation (6 litre min‐1)
Number of subjects: 20
Study 7544074 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (6 million KIU)
Number of subjects: 100
Study 7544074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2746403 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment
Number of subjects: 62
Study 2746403 — intervention group
Group type: COMPARATOR
Intervention: Mock adjustment (placebo)
Number of subjects: 62
Study 332090 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid
Number of subjects: 38
Study 332090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31812463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal influenza vaccine with 30 μg LTh(αK) adjuvant (group 1)
Number of subjects: 354
Study 31812463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal influenza vaccine with 45 μg LTh(αK) adjuvant (group 2)
Number of subjects: 354
Study 31812463 — intervention group
Group type: COMPARATOR
Intervention: Intranasal influenza vaccine with 22.5 μg HA antigen alone (control group 3)
Number of subjects: 354
Study 31225667 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVIE en m@rche
Number of subjects: 39
Study 31225667 — intervention group
Group type: COMPARATOR
Intervention: Control group (hyperlinks to public websites)
Number of subjects: 39
Study 28151883 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid users
Number of subjects: 8704
Study 28151883 — intervention group
Group type: COMPARATOR
Intervention: Non-glucocorticoid users (controls)
Number of subjects: 8704
Study 25985907 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 1534
Study 25985907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus atorvastatin 10 mg
Number of subjects: 1534
Study 25985907 — intervention group
Group type: EXPERIMENTAL
Intervention: No change in therapy
Number of subjects: 1534
Study 25985907 — intervention group
Group type: EXPERIMENTAL
Intervention: Double atorvastatin dose
Number of subjects: 1534
Study 25985907 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' treatment recommendations
Number of subjects: 1534
Study 23729226 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant with midazolam
Number of subjects: 45
Study 23729226 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant with erythromycin
Number of subjects: 45
Study 23729226 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant with dexamethasone (300 mg)
Number of subjects: 45
Study 21378081 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 65
Study 21378081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 19951408 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg daily of chicken type II collagen (CCII)
Number of subjects: 503
Study 19951408 — intervention group
Group type: COMPARATOR
Intervention: 10 mg once a week of methotrexate (MTX)
Number of subjects: 503
Study 19951408 — intervention group
Group type: EXPERIMENTAL
Intervention: CCII
Number of subjects: 503
Study 19951408 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 503
Study 19951408 — intervention group
Group type: EXPERIMENTAL
Intervention: CCII and MTX
Number of subjects: 503
Study 16983146 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma phospholipid (PL) DHA levels above the median
Number of subjects: 228
Study 16983146 — intervention group
Group type: COMPARATOR
Intervention: Plasma phospholipid (PL) DHA levels below the median
Number of subjects: 228
Study 12846051 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5‐15 mg of prednisolone (PRE) daily for one to three months followed by methotrexate (MTX) 5‐15 mg weekly if needed
Number of subjects: 245
Study 12846051 — intervention group
Group type: COMPARATOR
Intervention: sulfasalazine (SAL), supplemented with lowest possible corticosteroid dose if needed
Number of subjects: 245
Study 10496191 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month supervised and graded exercise program
Number of subjects: 33
Study 10496191 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 33
Study 8601981 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate (200 mg in 50 ml normal saline solution intravenously)
Number of subjects: 24
Study 8601981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 ml normal saline solution intravenously)
Number of subjects: 24
Study 1761642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG), 400 mg/kg daily for 3 days
Number of subjects: 29
Study 1761642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 7346177 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) treatment, given b.i.d. (twice daily)
Number of subjects: 8
Study 7346177 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) treatment, with dose reduction
Number of subjects: 8
Study 3002672 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 to 40 mg daily)
Number of subjects: 0
Study 3002672 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 to 240 mg daily)
Number of subjects: 0
Study 3002672 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril with hydrochlorothiazide
Number of subjects: 0
Study 3002672 — intervention group
Group type: COMPARATOR
Intervention: Propranolol with hydrochlorothiazide
Number of subjects: 0
Study 3002672 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 3002672 — intervention group
Group type: COMPARATOR
Intervention: Thiazide-induced conditions
Number of subjects: 0
Study 29925890 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-computer interface (BCI) coupled to functional electrical stimulation (FES)
Number of subjects: 0
Study 29925890 — intervention group
Group type: COMPARATOR
Intervention: Sham functional electrical stimulation (FES)
Number of subjects: 0
Study 26482590 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Kyphoplasty (BKP)
Number of subjects: 80
Study 26482590 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency-targeted Vertebral Augmentation (RF-TVA)
Number of subjects: 80
Study 24486366 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 0
Study 24486366 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 0
Study 24486366 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare provider recommendation
Number of subjects: 0
Study 24486366 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based practices as primary source of prenatal care
Number of subjects: 0
Study 24486366 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived interpersonal support for influenza immunization
Number of subjects: 0
Study 23012836 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 1 mg x kg(‐1) intravenously
Number of subjects: 60
Study 23012836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23012836 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 60
Study 20047897 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (20 microg kg(‐1) in 2 min)
Number of subjects: 20
Study 20047897 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (30 microg kg(‐1) in 15 min)
Number of subjects: 20
Study 20047897 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physostigmine and alfentanil (same doses)
Number of subjects: 20
Study 20047897 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (control)
Number of subjects: 20
Study 20047897 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 20
Study 20047897 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 20
Study 20047897 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physostigmine and alfentanil
Number of subjects: 20